Mirus Bio receives ISO 13485:2016 certification, underscoring the quality of processes used to support GMP product portfolio. Read more

About Us

At Mirus Bio, Innovation Never Ends

The number of applications that rely on delivery of nucleic acids into cells continues to expand and has become more diverse and complex. Replacing genes, re-programming T cells, producing novel biologics, and silencing mRNA translation, are just some of the noteworthy advances that depend on successful transfection.

That’s why we never stop innovating.

One Size Does Not Fit All

Each of these applications is unique and requires a transfection solution that is intentionally designed to deliver nucleic acid into a variety of cell types – consistently and efficiently.

Since our founding in 1995, we’ve been up to the challenge.


In both the biopharmaceutical and research industries


Published in over 10,000 peer-reviewed publications


Over 1,200 cell lines in which products have been used


56 U.S. and International
patents granted

A Legacy of Transfection Innovation

Since its founding in 1995, Mirus Bio has been meeting industry and customer needs through innovation, collaboration and partnerships.

March 26
Mirus Bio Named a Top Workplace by the Wisconsin State Journal

Mirus Bio has been named a Top Workplace 2024 by Wisconsin State Journal Top Workplaces. This award is based solely on employee feedback collected from a survey administered by an external organization.

Mirus Bio Receives ISO 13485:2016 Certification

Completion of this comprehensive certification process underscores the quality of the processes used to support the company’s GMP product portfolio

2023: Increase AAV vector production 2-4x with RevIT™ Enhancer
Kytopen and Mirus Bio Announce Partnership to Unlock New and Scalable Genome Engineering Capabilities for the Next-Generation of Living  Medicines

The two companies will collaborate to combine industry-leading technologies and tackle the non-viral delivery of highly complex genome engineering materials to help create human cellular medicines

2021: Transfection platform for production of AAV and lentivirus at clinical and commercial scales
2017: Transfection platform for production of AAV and lentivirus for research and preclinical applications
2015:  Introduced platform for protein production in CHO cells
2008: Sold in vivo siRNA delivery technology to Roche
Development of the first serum-compatible transfection reagent with TransIT®-LT1 Transfection reagent
1995: Mirus Bio founded